Optimal investment in a portfolio of HIV prevention programs

Medical Decision Making

Volumn 21, Issue 5, 2001, Pages 391-408

  Zaric, Gregory S ^a   Brandeau, Margaret L ^b  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b STANFORD UNIVERSITY   (United States)

Author keywords

AIDS; Cost benefit analysis; HIV; Prevention; Resource allocation

Indexed keywords

ARTICLE; HEALTH CARE COST; HEALTH CARE FINANCING; HEALTH PROGRAM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INFECTION PREVENTION; QUALITY OF LIFE;

EID: 0034827478     PISSN: 0272989X     EISSN: None     Source Type: Journal    
DOI: 10.1177/0272989X0102100506     Document Type: Article

References (90)

1. Community planning: A national strategy to improve HIV prevention programs
2. Decision making in HIV prevention community planning: An integrative review
3. Determining needs and setting priorities for HIV-affected and infected persons: Northeast Ohio and San Diego
4. Planning health care for people with HIV infection and AIDS
5. From cost-effectiveness ratios to resource allocation: Where to draw the line?
6. Mathematical programming for the efficient allocation of health care resources
7. An analysis of optimal resource allocation for HIV prevention among injection drug users and nonusers
8. Economic evaluation and HIV prevention community planning: A policy analyst's perspective
9. Allocating HIV prevention resources
10. The cost-effectiveness of HIV prevention targeting: How much more bang for the buck?
11. Resource allocation for epidemic control over short time horizons
12. HIV transmission and the cost effectiveness of methadone maintenance
13. Methadone maintenance and HIV prevention: A cost effectiveness analysis
14. Continuity and change within an HIV epidemic: Injecting drug users in New York City, 1984 through 1992
15. Reduction of AIDS risk among 41 heroin addicted female street prostitutes: Effects of free methadone maintenance
16. Economic methods for measuring the quality of life associated with HIV infection
17. Physicians' assessments of the utility of health states associated with human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infection
18. Health values of patients infected with human immunodeficiency virus: Relationship to mental health and physical functioning
19. Intravenous drug users and AIDS: Risk behaviors
20. A comparison of male and female intravenous drug users' risk behaviors for HIV infection
21. The consistency of self-reported HIV risk behavior among injection drug users
22. Sex, drugs and HIV counseling and testing: A prospective study of behavior-change among methadone-maintenance clients in New England
23. Human immuno-deficiency virus type 1 antibody status and changes in risk behavior among drug users
24. High-risk sexual behaviors of intravenous drug users in- and out-of-treatment: Implications for the spread of HIV infection
25. Trends in risk behavior and HIV seroprevalence in heterosexual injection drug users in San Francisco, 1986-1992
26. Ineffectiveness of AIDS education and HIV antibody testing in reducing high-risk behaviors among injection drug users
27. The sexual behavior of men in the United States
28. Multiple sexual partners among Hispanics in high-risk cities
29. Effect of HIV counseling and testing on sexually transmitted diseases and condom use in an urban adolescent population
30. Multipte sexual partners among young adults in high-risk cities
31. Multiple sexual partners among blacks in high-risk cities
32. The sexual practices of US adults: Results from a national survey
33. Long-term trends in self-reported HIV risk behavior: Injection drug users in Los Angeles, 1987 through 1995
34. Sexual activity, condom use and AIDS awareness among adolescent males
35. Sexual ethics: Disclosure of HIV-positive status to partners
36. A meta-analysis of condom effectiveness in reducing sexually transmitted HIV
37. Effectiveness of condoms in preventing HIV transmission
38. A model-based estimate of HIV infectivity via needle sharing
39. HIV risk-related sex behaviors among injection drug users, crack smokers, and injection drug users who smoke crack
40. Substance abuse treatment entry, retention and effectiveness: Out-of-treatment opiate injection drug users
41. Racial/ethnic differences in HIV-1 seroprevalence and risky behaviors among intravenous drug users in a multisite study
42. HIV infection and cocaine use in methadone maintained and untreated intravenous drug users
43. Methadone maintenance and the likelihood of risky needle-sharing
44. Trends of HIV-1 risk reduction among initiates into intravenous drug use 1982-1987
45. Behavioural change in injecting drug users: Evaluation of an HIV/AIDS education programme
46. Methadone maintenance: Some treatment programs are not effective; greater federal oversight needed
47. Reducing the risk of AIDS through methadone maintenance treatment
48. Methadone maintenance treatment: A ten-year perspective
49. Abstinence following detoxification and methadone maintenance treatment
50. Methadone-assisted rehabilitation of Swedish heroin addicts
51. A follow-up study of heroin addicts five years after first admission to a methadone treatment program
52. Long-term follow-up of clients of high- and low-dose methadone programs
53. Drug treatment on demand - Not
54. Specification of a hospital production function
55. A production function for dental services: Estimation and economic implications
56. Let the needles do the talking! Evaluating the New Haven needle exchange
57. Economic analysis of needle exchange
58. Gender differences in high-risk sex behaviors among heterosexual drug injectors and crack smokers
59. Impact of a high school condom availability program on sexual attitudes and behaviors
60. Distributed decision support using a web-based interface: Prevention of sudden cardiac death
61. HIV infection and AIDS risk behaviors among intravenous drug users entering methadone treatment in selected US cities
62. HIV infection and AIDS risk behaviors among injecting drug users entering methadone treatment: An update
63. Consistent condom use in relationships between seropositive injecting drug users and sex partners who do not inject drugs
64. Male-to-female transmission of human immunodeficiency virus
65. Female-to-male transmission of human immunodeficiency virus
66. Heterosexual transmission of human immunodeficiency virus (HIV) in northern California: Results from a ten-year study
67. Infectivity of HIV by anal and oral intercourse among homosexual men: Estimates from a prospective study in San Francisco
68. A longitudinal study of human immunodeficiency virus transmission by heterosexual partners
69. Epidemiological parameters of HIV transmission
70. Differences in mortality rates and causes of death between HIV positive and HIV negative intravenous drug users
71. Mortality in heroin addiction: Impact of methadone treatment
72. Mortality trends in a cohort of opiate addicts, Catalonia, Spain
73. The effects of antiretroviral therapy and opportunistic illness primary chemoprophylaxis on survival after AIDS
74. Survival after diagnosis of AIDS: A prospective observational study of 2625 patients
75. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine
76. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy
77. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus and CD4 cell counts of 200 per cubic millimeter or less
78. Improved survival among HIV-infected patients after initiation of triple-drug antiretroviral regimens
79. Increasing survival time after AIDS in Italy: The role of new combination antiretroviral therapies